Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes - PubMed (original) (raw)

doi: 10.1007/s00125-010-2028-x. Epub 2011 Jan 21.

K Shikata, H U Kataoka, T Takatsuka, S Miyamoto, M Sasaki, N Kajitani, S Nishishita, K Sarai, D Hirota, C Sato, D Ogawa, H Makino

Affiliations

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

R Kodera et al. Diabetologia. 2011 Apr.

Abstract

Aims/hypothesis: Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose.

Methods: We administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro.

Results: Exendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells.

Conclusions/interpretation: These results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Diabetologia. 2009 Apr;52(4):691-7 - PubMed
    1. Diabetes Care. 2005 Dec;28(12):2890-5 - PubMed
    1. Nephrol Dial Transplant. 2003 Feb;18(2):265-72 - PubMed
    1. Gastroenterology. 2007 May;132(6):2131-57 - PubMed
    1. N Engl J Med. 1988 May 19;318(20):1315-21 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources